AOD-9604 Cannabis Interaction Profile: What You Need to Know

What Is AOD-9604 and How Does It Work?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment (residues 176-191) of human growth hormone. It was originally developed by Monash University researchers and later advanced clinically by Metabolic Pharmaceuticals in Australia. The compound targets adipose tissue directly, stimulating beta-3 adrenergic receptors to increase lipolysis while inhibiting the maturation of pre-adipocytes into fat cells.

Mechanism of Fat Loss

AOD-9604 does not bind to the growth hormone receptor in the same way as full-length HGH. Published animal pharmacology in Biochemical and Biophysical Research Communications demonstrated that the peptide retains the lipolytic but not the growth-promoting activity of the parent hormone, avoiding the insulin-resistance concerns associated with exogenous HGH use. [1]

The peptide does not raise serum IGF-1 at doses studied in humans (up to 9,000 mcg/day orally in Phase II), and fasting blood glucose remained statistically indistinguishable from placebo across those trials. [2]

Regulatory and Approval Context

The FDA has not approved AOD-9604 as a drug. The agency granted it GRAS (Generally Recognized as Safe) status for use as a food additive in 2014, a classification that covers food-grade use and does not constitute therapeutic approval. [3] Prescribers in the United States who include AOD-9604 in weight-management protocols do so under compounding pharmacy frameworks. Patients should confirm the legal and regulatory status in their jurisdiction before use.

How Cannabis Affects the Body: The Relevant Pharmacology

Cannabis contains more than 100 cannabinoids. For the purposes of a drug-interaction analysis, two are most relevant: delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent, and cannabidiol (CBD), which has distinct receptor pharmacology.

THC and the Endocannabinoid System

THC binds with high affinity to cannabinoid type-1 (CB1) receptors throughout the central nervous system and peripheral tissues. Hypothalamic CB1 activation by THC suppresses the release of anorexigenic peptides, increases ghrelin sensitivity, and sharply raises caloric intake. A controlled crossover study published in Psychopharmacology (N=30 healthy adults) found that smoked cannabis increased ad libitum caloric intake by approximately 40% in the 24 hours after use. [4]

CBD and CYP Enzyme Inhibition

CBD inhibits CYP2C9, CYP2C19, and CYP3A4 in vitro. At clinically relevant plasma concentrations from high-dose pharmaceutical CBD (Epidiolex, 10-20 mg/kg/day), these inhibitory effects have produced measurable increases in plasma concentrations of co-administered CYP substrates such as clobazam. [5]

This matters for the AOD-9604 interaction analysis because AOD-9604, as a peptide, is not metabolized by CYP450 enzymes. It is broken down by circulating and tissue proteases. CBD's CYP inhibition is therefore unlikely to alter AOD-9604 plasma exposure.

Direct Pharmacokinetic Interaction: Is There One?

The short answer is: probably not. Pharmacokinetic interactions occur when one drug alters the absorption, distribution, metabolism, or elimination of another.

Why Peptide Metabolism Differs

Peptides are not substrates for hepatic CYP450 enzymes. AOD-9604, injected subcutaneously, is absorbed through capillary uptake, distributed to peripheral tissues, and cleared by endopeptidases and exopeptidases. The oral form undergoes partial degradation in the gut before systemic absorption. Neither route produces a metabolic intermediate that cannabis cannabinoids could meaningfully inhibit or induce. [6]

Protein Binding Displacement

THC is highly protein-bound (approximately 97% bound to albumin and lipoproteins). AOD-9604, as a small peptide, has relatively low plasma protein binding. Protein-binding displacement interactions require that both drugs compete for the same binding sites. The chemical characteristics of THC and AOD-9604 make this scenario unlikely, though no dedicated displacement study has been conducted.

Absorption-Level Considerations

For patients using the oral lozenge or capsule form of AOD-9604, cannabis smoking could theoretically cause transient changes in gut motility that alter absorption timing. Cannabis slows gastric emptying at higher THC doses. [7] This effect is modest and may cause a minor delay in oral AOD-9604 peak plasma time without affecting total bioavailability in a clinically meaningful way.

The table below summarizes the pharmacokinetic interaction assessment across administration routes.

| Interaction Axis | Subcutaneous AOD-9604 | Oral AOD-9604 | |---|---|---| | CYP450 metabolism affected by CBD? | No | No | | P-glycoprotein substrate? | Unlikely | Uncertain | | Protein-binding displacement by THC? | Low risk | Low risk | | Gastric motility effect (THC)? | Not applicable | Minor delay possible | | Overall PK interaction risk | Low | Low-to-minimal |

Pharmacodynamic Interaction: The Real Clinical Concern

Even when two compounds do not alter each other's blood levels, they can work against each other at the level of physiological effect. This is the pharmacodynamic interaction, and it is the central issue with AOD-9604 and cannabis.

Cannabis-Driven Appetite Increase vs. AOD-9604 Fat-Loss Goals

AOD-9604 is prescribed specifically to reduce fat mass. Cannabis, through CB1-mediated disinhibition of appetite circuits, reliably increases caloric consumption. The tension between these two effects is not hypothetical.

A 2020 analysis of the National Health and Nutrition Examination Survey (NHANES, N=13,679) found that regular cannabis users consumed an average of 264 additional kilocalories per day compared with non-users, even after adjusting for physical activity and demographic covariates. [8] Over the course of a 12-week AOD-9604 protocol, that caloric surplus could add 2.5-3 lbs of body weight, partially or fully offsetting peptide-mediated lipolysis.

Hormonal Overlap: Ghrelin and Appetite Signaling

THC increases circulating ghrelin, the primary hunger-signaling peptide. A placebo-controlled study in Diabetes, Obesity and Metabolism (N=40) found that smoked cannabis raised fasting ghrelin levels by 37% within 90 minutes of use. [9] AOD-9604 does not directly suppress ghrelin. Patients who combine cannabis use with AOD-9604 may experience appetite stimulation that the peptide has no pharmacological mechanism to counter.

Sleep Architecture and Growth Hormone Pulse

AOD-9604 administered in the evening may work in partial synchrony with the nocturnal growth hormone surge that occurs during deep sleep (stage N3). THC, while it reduces sleep onset latency, suppresses REM sleep and has been shown in polysomnographic studies to blunt slow-wave sleep in chronic users. [10] Reduced slow-wave sleep is associated with attenuated nocturnal growth hormone secretion. Whether this translates to reduced AOD-9604 efficacy is not established, but the theoretical pathway is plausible.

Can I Drink on AOD-9604?

Alcohol does not appear to produce a direct pharmacokinetic interaction with AOD-9604 for the same reasons that cannabis does not: the peptide avoids hepatic CYP450 metabolism. However, alcohol introduces several pharmacodynamic and practical concerns.

Hepatic Stress and Metabolic Context

Alcohol is metabolized primarily by alcohol dehydrogenase and CYP2E1 in the liver, producing acetaldehyde and subsequently acetate. Chronic heavy alcohol use impairs hepatic gluconeogenesis and lipid handling. Since AOD-9604 is being used to reduce adiposity, adding hepatic fat accumulation from regular alcohol consumption creates a counter-productive metabolic environment. The CDC defines heavy drinking as more than 14 drinks per week for men and more than 7 per week for women. [11]

Cortisol, Insulin, and Fat Storage

Alcohol acutely raises cortisol and transiently impairs insulin signaling in muscle and adipose tissue. Elevated cortisol promotes visceral fat accumulation. A study in Obesity Research (N=225) found that men who consumed 2 or more alcoholic drinks daily had significantly higher visceral adiposity index scores than abstainers, independent of total caloric intake. [12]

Practical Adherence Considerations

Alcohol use is associated with poorer adherence to injection-based protocols. Patients who drink heavily are more likely to miss doses, store medications improperly, or fail to maintain the caloric discipline that amplifies AOD-9604 outcomes. These are behavioral rather than biochemical interactions, but they carry real clinical weight.

What the Absence of Direct Evidence Means for Clinical Practice

No peer-reviewed human trial has co-administered AOD-9604 and cannabis or alcohol. This absence of evidence does not confirm safety or confirm harm. It creates a region of genuine clinical uncertainty that prescribers and patients must manage based on mechanistic reasoning and indirect data.

Applying the Precautionary Framework

The HealthRX medical team uses the following framework when counseling patients who use cannabis or alcohol alongside peptide weight-loss protocols:

1. Quantify use. Frequency, dose (mg THC per session), and timing relative to AOD-9604 administration all affect risk level. Occasional use (<2 sessions per week) carries a different pharmacodynamic burden than daily use.
2. Evaluate the primary therapeutic goal. If the patient is using AOD-9604 specifically for fat reduction, cannabis-driven appetite increases represent a direct counter-force. If the indication is musculoskeletal (some off-label use explores AOD-9604's cartilage-protective properties), the appetite concern is less operationally relevant.
3. Assess metabolic status. Patients with dyslipidemia, non-alcoholic fatty liver disease (NAFLD), or insulin resistance face additive metabolic risk from cannabis and especially alcohol use.
4. Time the doses thoughtfully. If cannabis is used recreationally and the patient is unwilling to discontinue, administering AOD-9604 in the morning and keeping cannabis use to evening hours may limit the direct appetite-to-dosing overlap window.

Guideline Perspectives on Cannabis and Metabolic Health

The Endocrine Society's 2023 clinical practice guidelines on obesity pharmacotherapy do not specifically address peptide-cannabis co-administration, but they do state that clinicians "should counsel patients on behavioral and substance use factors that may attenuate pharmacotherapy outcomes." [13] Cannabis-driven hyperphagia fits squarely within that recommendation.

The American Heart Association's 2020 scientific statement on cannabis and cardiovascular risk notes that THC produces acute tachycardia, mild blood pressure elevation, and increased cardiac oxygen demand. [14] For AOD-9604 patients who have cardiovascular comorbidities, this adds an independent safety consideration beyond the peptide interaction question.

Special Populations and Considerations

Patients Using Cannabis for Medical Indications

Some patients using AOD-9604 may be prescribed cannabis for chronic pain, anxiety, or nausea. In these cases, the risk-benefit calculation shifts. A prescriber managing both agents should consider:

• Substituting high-CBD, low-THC formulations where possible, since CBD does not activate CB1 appetite pathways with the same potency as THC.
• Scheduling cannabis use in time windows that minimize overlap with peak AOD-9604 activity.
• Monitoring weight trajectory monthly, using DEXA scan or bioelectrical impedance where available, to detect early signs that appetite stimulation is offsetting fat loss.

Patients Who Are Also Using Semaglutide or Tirzepatide

Combination peptide protocols are increasingly common. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have demonstrated substantial appetite suppression through GLP-1 and GIP receptor agonism. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight loss at 72 weeks. [15] Patients on these GLP-1 class agents may experience a partial pharmacodynamic offset of cannabis-driven appetite stimulation, because GLP-1 receptor agonists powerfully suppress the hypothalamic appetite circuits that THC activates. This does not eliminate the concern entirely, but it changes the clinical picture.

Adolescents and Young Adults

AOD-9604 is not indicated in pediatric populations. However, younger adult patients (<25 years) using cannabis face additional considerations: the developing brain's endocannabinoid system is more sensitive to THC-related disruption, and early-onset heavy cannabis use has been associated with attenuated GH pulse amplitude in longitudinal data from the Christchurch Health and Development Study. [16]

Monitoring Recommendations for Patients Who Choose to Continue Cannabis Use

If a patient discloses ongoing cannabis use and both patient and prescriber decide to continue AOD-9604, the following monitoring approach is reasonable based on pharmacodynamic risk:

Baseline and Follow-Up Metrics

• Body composition (weight, waist circumference, or DEXA) at baseline, week 4, and week 12.
• Fasting ghrelin if available at the prescribing institution, to establish whether appetite signaling is disproportionately elevated.
• Liver function panel if alcohol co-use is present.
• Sleep quality questionnaire (PSQI or Epworth) at baseline, given cannabis effects on sleep architecture.

Dietary Tracking

Patients using cannabis should log caloric intake on the days they use it versus days they do not. A caloric diary with a minimum 2-week baseline can quantify the actual appetite-stimulation burden and allow the prescribing team to adjust dietary targets accordingly.

Key Takeaways for Patients and Prescribers

AOD-9604 and cannabis do not appear to produce a clinically significant pharmacokinetic interaction. The peptide's clearance through proteolytic pathways bypasses the CYP450 system where cannabinoids exert their primary metabolic effects.

The pharmacodynamic picture is more complicated. Cannabis, through CB1 activation and ghrelin elevation, increases appetite in a way that directly opposes fat-loss goals. Alcohol adds hepatic and hormonal counter-pressure. Neither concern rises to the level of an absolute contraindication based on current evidence, but both deserve structured, honest conversation between patient and prescriber before and during therapy.

Patients using cannabis for medical reasons should work with their prescriber to identify low-THC formulations and to monitor body composition monthly during AOD-9604 therapy. Patients using cannabis recreationally should be counseled that even occasional use (<2 sessions per week) may blunt outcomes when caloric surplus accompanies it.

For any patient starting AOD-9604 who currently uses cannabis or alcohol: disclose fully, measure consistently, and adjust protocol variables based on actual body composition data rather than assumptions.